Through a step-wise trial design we demonstrated the safety, tumor-selective trafficking, and anti-tumor activity of RGD-A-TNF to tumor blood vessels and targeted expression of TNFα in a relevant clinical setting. The gene discussed is TNF; the disease is neoplasm.